Publicaciones (20) Publicaciones en las que ha participado algún/a investigador/a

2016

  1. Certolizumab Pegol, a New Anti-TNF-α in the Armamentarium against Ocular Inflammation

    Ocular Immunology and Inflammation, Vol. 24, Núm. 2, pp. 167-172

  2. Characterization of patients with lupus nephritis included in a large cohort from the Spanish society of rheumatology registry of patients with systemic lupus erythematosus (RELESSER)

    Medicine (United States), Vol. 95, Núm. 9

  3. Combination of Intra-Articular and Intraosseous Injections of Platelet Rich Plasma for Severe Knee Osteoarthritis: A Pilot Study

    BioMed Research International, Vol. 2016

  4. Computational Lexical Analysis of the Language Commonly Used to Describe Gout

    Arthritis Care and Research, Vol. 68, Núm. 6, pp. 763-768

  5. Cost-effectiveness analysis of febuxostat in patients with gout in Spain

    Journal of Medical Economics, Vol. 19, Núm. 6, pp. 604-610

  6. Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises

    Arthritis Care and Research, Vol. 68, Núm. 5, pp. 667-672

  7. Diagnostic arthrocentesis for suspicion of gout is safe and well tolerated

    Journal of Rheumatology, Vol. 43, Núm. 1, pp. 150-153

  8. Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children

    Journal of Allergy and Clinical Immunology, Vol. 138, Núm. 6, pp. 1752-1755

  9. Epidemiology and health-related services

    Current Opinion in Rheumatology, Vol. 28, Núm. 2, pp. 104-109

  10. Estándares de calidad asistencial para las consultas externas de reumatología. El proyecto EXTRELLA

    Reumatologia Clinica, Vol. 12, Núm. 5, pp. 248-255

  11. Evaluation of the impact of nursing clinics in the rheumatology services

    Rheumatology International, Vol. 36, Núm. 9, pp. 1309-1317

  12. Febuxostat for the chronic management of hyperuricemia in patients with gout

    Expert Review of Clinical Pharmacology, Vol. 9, Núm. 5, pp. 665-673

  13. Fibromyalgia prevalence and related factors in a large registry of patients with systemic lupus erythematosus

    Clinical and Experimental Rheumatology, Vol. 34, pp. 40-47

  14. Imaging of gout: New tools and biomarkers?

    Best Practice and Research: Clinical Rheumatology, Vol. 30, Núm. 4, pp. 638-652

  15. Lesinurad in combination with allopurinol: Results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol

    Annals of the Rheumatic Diseases, Vol. 75, Núm. 6, pp. 1074-1080

  16. Performance of classification criteria for gout in early and established disease

    Annals of the Rheumatic Diseases, Vol. 75, Núm. 1, pp. 178-182

  17. Relationship between damage clustering and mortality in systemic lupus erythematosus in early and late stages of the disease: Cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry

    Rheumatology (United Kingdom), Vol. 55, Núm. 7, pp. 1243-1250

  18. Survey Definitions of Gout for Epidemiologic Studies: Comparison With Crystal Identification as the Gold Standard

    Arthritis Care and Research, Vol. 68, Núm. 12, pp. 1894-1898

  19. The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry

    Arthritis and Rheumatology, Vol. 68, Núm. 11, pp. 2795-2805

  20. Urate lowering therapies in the treatment of gout: A systematic review and meta-Analysis

    European Review for Medical and Pharmacological Sciences, Vol. 20, Núm. 5, pp. 983-992